Seer, Inc., a life sciences company, engages in developing and commercializing products for researchers to unlock biological information. The company develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that provides workflow to make proteomic profiling, and the analysis of the samples needed to characterize the nature of the proteome. It intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. Seer, Inc. has a collaboration agreement with Discovery Life Sciences, LLC. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
IPO Year: 2020
Exchange: NASDAQ
Website: seer.bio
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/5/2023 | $10.00 | Neutral | JP Morgan |
1/4/2023 | $9.00 → $6.50 | Neutral → Underperform | BofA Securities |
8/11/2022 | $20.00 → $12.00 | Overweight → Neutral | JP Morgan |
3/1/2022 | $23.00 → $21.00 | Equal-Weight | Morgan Stanley |
2/15/2022 | $46.00 → $23.00 | Equal-Weight | Morgan Stanley |
10/15/2021 | Outperform | Cowen | |
8/13/2021 | $55.00 → $50.00 | Equal-Weight | Morgan Stanley |
REDWOOD CITY, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY. Seer's management is scheduled to participate in a fireside chat on Thursday, September 5th at 4:05 p.m. Eastern Time / 1:05 p.m. Pacific Time. A live webcast of the session will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the conference. About SeerSeer is a life sciences co
REDWOOD CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Dr. Nicolas Roelofs to serve on its Board of Directors. "Nick is a fantastic addition to our board, bringing over 35 years of broad operational and advisory experience with leading healthcare, life science tools, and diagnostics companies," said Omid Farokhzad, Chair and CEO of Seer. "His extensive experience and insights will be valuable as we advance our mission of opening up a new gateway to the proteome." "I'm excited to work with the Seer team and leverage my experience in the life
REDWOOD CITY, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Canaccord Genuity 44th Annual Growth Conference in Boston, MA. Seer's management is scheduled to participate in a fireside chat on Wednesday, August 14th at 3:00 p.m. Eastern Time / 12:00 p.m. Pacific Time. A live webcast of the session will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the conference. About SeerSeer is a life sciences company
REDWOOD CITY, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Achieved revenue of $3.1 million for the second quarter of 2024Launched the Seer Technology Access Center (STAC) in Europe, providing researchers with end-to-end services from sample to dataDemonstrated how the Proteograph Product Suite can uncover differentiated insights into plasma proteomic changes that occur during spaceflight through customer publications in Nature and Nature CommunicationsEnded the quarter with $344.6 m
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the second quarter 2024 on Thursday, August 8, 2024. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the event. About SeerSeer is a life sciences company developing transformative products that open a new gateway to
Secretome profiles from SpaceX Inspiration4 mission show alterations in oxidative stress, brain homeostasis, and coagulation Creation of first-of-its-kind comprehensive atlas of molecular and physiological multiomic profiles available from multiple spaceflight missions REDWOOD CITY, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced three publications highlighting studies led by Christopher Mason, Ph.D. that show how Seer's Proteograph Product Suite can uncover novel insights into plasma proteomic changes that occur during spaceflight. The studies further dem
REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Achieved revenue of $3.1 million for the first quarter of 2024Announced the expansion of the Seer Technology Access Center (STAC) program to Europe, providing researchers with end-to-end services from sample to dataFurther validated the power of the Proteograph Product Suite with three peer-reviewed publications in leading journals since the beginning of the year, with additional manuscripts available on pre-print serversLaunc
New Seer Technology Access Center to open in Bonn, Germany Provides life sciences researchers conducting proteomic studies full-service access to the Seer Proteograph™ Product Suite and mass spectrometry REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, announced the launch of the Seer Technology Access Center (STAC) in Bonn, Germany, providing the European biopharma and life sciences communities with service programs and the latest mass spectrometry technologies to optimize deep, unbiased proteomic studies. The new facility, opening in June, will be located at Li
REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2024 on Wednesday, May 8, 2024. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the event. About SeerSeer is a life sciences company developing transformative products that open a new gateway to th
REDWOOD CITY, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2023. Recent Highlights Achieved revenue of $4.4 million for the fourth quarter of 2023, a decrease of 4% over the fourth quarter of 2022, and $16.7 million for the full year 2023, an increase of 8% over the full year 2022Shipped 23 instruments during 2023, bringing cumulative instruments shipped to 62 as of December 31, 2023Expanded internationally with the addition of four new distributors and partnersFirst peer-reviewed customer
REDWOOD CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Dr. Nicolas Roelofs to serve on its Board of Directors. "Nick is a fantastic addition to our board, bringing over 35 years of broad operational and advisory experience with leading healthcare, life science tools, and diagnostics companies," said Omid Farokhzad, Chair and CEO of Seer. "His extensive experience and insights will be valuable as we advance our mission of opening up a new gateway to the proteome." "I'm excited to work with the Seer team and leverage my experience in the life
REDWOOD CITY, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a life sciences company commercializing a disruptive new platform for proteomics, announced today the appointment of Scott D. Thomas as Chief Commercial Officer effective March 21, 2022. Mr. Thomas joins Seer from Singular Genomics, where he served as Senior Vice President, Sales and Marketing. Prior to Singular, he spent over two decades with increasing commercial responsibilities within the life sciences industry, including 11 years at Illumina. "I'm thrilled to welcome Scott, whose leadership and breadth of expertise in the commercialization of life sciences tools complements the balance of our talented
REDWOOD CITY, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (NASDAQ:SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Meeta Gulyani to serve on its Board of Directors. Ms. Gulyani is currently Executive Vice President, Head of Strategy, Business Development and Transformation for the Life Science business of Merck KGaA, Darmstadt, Germany, a global science and technology company, which operates as MilliporeSigma in the U.S. and Canada. "Meeta is a seasoned life sciences and pharma leader with global experience across markets, including Asia, an important market for Seer, and we are really pleased to welcome Me
REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (NASDAQ:SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Rachel Haurwitz, Ph.D. to serve on its Board of Directors, effective November 8, 2021. Dr. Haurwitz is currently CEO of Caribou Biosciences, Inc. a clinical-stage biopharmaceutical company developing genome-edited off-the-shelf immune cell therapies for the treatment of cancer. Concurrent with this appointment, David Singer will step down from the Board of Directors. "We're delighted to welcome Rachel to our Board of Directors. Rachel is a highly accomplished and distinguished scientist and CEO
REDWOOD CITY, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Achieved revenue of $3.1 million for the second quarter of 2024Launched the Seer Technology Access Center (STAC) in Europe, providing researchers with end-to-end services from sample to dataDemonstrated how the Proteograph Product Suite can uncover differentiated insights into plasma proteomic changes that occur during spaceflight through customer publications in Nature and Nature CommunicationsEnded the quarter with $344.6 m
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the second quarter 2024 on Thursday, August 8, 2024. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the event. About SeerSeer is a life sciences company developing transformative products that open a new gateway to
REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Achieved revenue of $3.1 million for the first quarter of 2024Announced the expansion of the Seer Technology Access Center (STAC) program to Europe, providing researchers with end-to-end services from sample to dataFurther validated the power of the Proteograph Product Suite with three peer-reviewed publications in leading journals since the beginning of the year, with additional manuscripts available on pre-print serversLaunc
REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter 2024 on Wednesday, May 8, 2024. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the event. About SeerSeer is a life sciences company developing transformative products that open a new gateway to th
REDWOOD CITY, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2023. Recent Highlights Achieved revenue of $4.4 million for the fourth quarter of 2023, a decrease of 4% over the fourth quarter of 2022, and $16.7 million for the full year 2023, an increase of 8% over the full year 2022Shipped 23 instruments during 2023, bringing cumulative instruments shipped to 62 as of December 31, 2023Expanded internationally with the addition of four new distributors and partnersFirst peer-reviewed customer
REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the fourth quarter and full year 2023 on Thursday, February 29, 2024. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the event. About SeerSeer is a life sciences company developing transformative products that open
REDWOOD CITY, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights Achieved revenue of $4.2 million for the third quarter of 2023, an increase of 5% over the prior year periodExpanded geographically with two new partners - Danyel Biotech in Israel and GeneTiCA in Eastern EuropeAdded Panome Bio to Centers of Excellence program to deliver innovative multi-omics servicesDemonstrated value of Proteograph Product Suite through increased customer publications available on bioRxivReceived ISO 27001 cer
REDWOOD CITY, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the third quarter of 2023 after market close on Tuesday, November 7, 2023. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the event. About SeerSeer™ is a life sciences company developing transformative products that open a
REDWOOD CITY, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the second quarter ended June 30, 2023. Recent Highlights Achieved revenue of $4.0 million for the second quarter of 2023, an increase of 11% over the prior year periodLaunched the Proteograph XT Assay Kit, enabling rapid proteomics across a range of sample types and species with unprecedented resolution and more than doubling the throughput without compromising performanceIntroduced the Seer Technology Access Center, or STAC, providing mass spec services and end-to-end solutions for cu
REDWOOD CITY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the second quarter of 2023 after market close on Tuesday, August 8, 2023. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer's website at investor.seer.bio. An archived replay will be available on the company's website following the event. About SeerSeer is a life sciences company developing transformative products that o
8-K - Seer, Inc. (0001726445) (Filer)
10-Q - Seer, Inc. (0001726445) (Filer)
8-K - Seer, Inc. (0001726445) (Filer)
8-K - Seer, Inc. (0001726445) (Filer)
8-K - Seer, Inc. (0001726445) (Filer)
8-K - Seer, Inc. (0001726445) (Filer)
144 - Seer, Inc. (0001726445) (Subject)
10-Q - Seer, Inc. (0001726445) (Filer)
8-K - Seer, Inc. (0001726445) (Filer)
ARS - Seer, Inc. (0001726445) (Filer)
4 - Seer, Inc. (0001726445) (Issuer)
3 - Seer, Inc. (0001726445) (Issuer)
4 - Seer, Inc. (0001726445) (Issuer)
4 - Seer, Inc. (0001726445) (Issuer)
4 - Seer, Inc. (0001726445) (Issuer)
4 - Seer, Inc. (0001726445) (Issuer)
4 - Seer, Inc. (0001726445) (Issuer)
4 - Seer, Inc. (0001726445) (Issuer)
4 - Seer, Inc. (0001726445) (Issuer)
4 - Seer, Inc. (0001726445) (Issuer)
Seer (NASDAQ:SEER) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.34) by 5.88 percent. This is a 15.79 percent increase over losses of $(0.38) per share from the same period last year. The company reported quarterly sales of $3.066 million which missed the analyst consensus estimate of $3.800 million by 19.32 percent. This is a 24.35 percent decrease over sales of $4.053 million the same period last year.
Morgan Stanley analyst Yuko Oku reinstates Seer (NASDAQ:SEER) with a Equal-Weight and announces $7 price target.
Seer (NASDAQ:SEER) reported its Q4 earnings results on Thursday, February 29, 2024 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Seer beat estimated earnings by 24.0%, reporting an EPS of $-0.28 versus an estimate of $-0.37. Revenue was down $166 thousand from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.07 which was followed by a 5.0% drop in the share price the next day. Here's a look at Seer's past performance: Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022 EPS Estimate -0.40 -0.39 -0.38 -0.43 EPS Actual -0.33 -0.37 -0.38 -0.36 Revenue Estimate 4.30M 5.07M 3.92M 3.87M Revenue Actual 4.16M 4.01M 4.0
Seer (NASDAQ:SEER) reported quarterly losses of $(0.280) per share which beat the analyst consensus estimate of $(0.380) by 26.32 percent. This is a 22.22 percent increase over losses of $(0.360) per share from the same period last year. The company reported quarterly sales of $4.438 million which beat the analyst consensus estimate of $4.050 million by 9.58 percent. This is a 3.61 percent decrease over sales of $4.604 million the same period last year.
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million. • NB Bancorp (NASDAQ:NBBK) is likely to report earnings for its Fiscal Year 2023. • Verona Pharma (NASDAQ:VRNA) is projected to report quarterly loss at $0.26 per share on revenue of $0. • iHuman (NYSE:IH) is estimated to report earnings for its fourth quarter. • argenx (NASDAQ:ARGX) is estimated to report quarterly loss at $1.71 per share on revenue of $364.75 million. • Titan Intl (NYSE:TWI) is expected to report quarterly earnings at $0.28 per share on revenue of $413.57 million. • Canadian Imperial Bank (NYSE:CM) is projected to repo
The Nasdaq 100 closed higher by around 1% on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company’s prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision. Below is a look at a few recent notable insider sales. For more, check out Benzinga's insider transactions platform. Zoom Video Communications The Trade: Zoom Video Communications, Inc. (NASDAQ:ZM) CEO Eric S. Yuan sold a total of 4,842 shares at
Study led by Weill Cornell Medicine demonstrates identification of protein altering variants for population-scale protein quantitative trait loci (pQTL) studies Proteograph Product Suite enables scalable deep, unbiased proteomics by mass spectrometry and overcomes the limitations of affinity-based methodsREDWOOD CITY, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ:SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced a publication in Nature Communications from a study led by Weill Cornell Medicine showing Seer's Proteograph workflow to potentially unveil novel proteogenomic insights into genetics-based drug and biomarke
JP Morgan resumed coverage of Seer with a rating of Neutral and set a new price target of $10.00
BofA Securities downgraded Seer from Neutral to Underperform and set a new price target of $6.50 from $9.00 previously
JP Morgan downgraded Seer from Overweight to Neutral and set a new price target of $12.00 from $20.00 previously
Morgan Stanley reiterated coverage of Seer with a rating of Equal-Weight and set a new price target of $21.00 from $23.00 previously
Morgan Stanley reiterated coverage of Seer with a rating of Equal-Weight and set a new price target of $23.00 from $46.00 previously
Cowen resumed coverage of Seer with a rating of Outperform
Morgan Stanley reiterated coverage of Seer with a rating of Equal-Weight and set a new price target of $50.00 from $55.00 previously
Morgan Stanley reiterated coverage of Seer with a rating of Equal-Weight and set a new price target of $55.00 from $60.00 previously
Morgan Stanley reiterated coverage of Seer with a rating of Equal-Weight and set a new price target of $60.00 from $65.00 previously
SC 13G/A - Seer, Inc. (0001726445) (Subject)
SC 13G/A - Seer, Inc. (0001726445) (Subject)
SC 13G/A - Seer, Inc. (0001726445) (Subject)
SC 13G/A - Seer, Inc. (0001726445) (Subject)
SC 13G/A - Seer, Inc. (0001726445) (Subject)
SC 13G/A - Seer, Inc. (0001726445) (Subject)
SC 13G/A - Seer, Inc. (0001726445) (Subject)
SC 13G/A - Seer, Inc. (0001726445) (Subject)
SC 13G/A - Seer, Inc. (0001726445) (Subject)
SC 13G/A - Seer, Inc. (0001726445) (Subject)